Vasoconstriction Disorder of Extremities Clinical Trial
— AURIXOfficial title:
Response of the Autonomic Nervous System to Auricular Stimulation of the Vagus Nerve (x)
| Verified date | January 2022 |
| Source | Hôpital Européen Marseille |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
While invasive vagal stimulation has proven its therapeutic effectiveness over the past 20 years, particularly in the treatment of epilepsy or depression, its implementation is hampered by the high cost, high technicality and sometimes significant side effects. Non-invasive vagal stimulation, most often electric, is a less expensive therapeutic alternative and easier to implement, although the level of evidence is lower than that of invasive stimulation. Some so-called traditional therapies, such as acupuncture, also stimulate certain parts of the ear by mechanical means, most often by puncturing the ear or the concha. In these traditional therapies, more than one hundred stimulation points have been described, each precisely positioned according to an empirical topography. However, electrical non-invasive stimulation recognizes only three areas of interest on the ear, which are the areas of sensitive innervation, namely the afferences of the vagus nerve in the concha, which is the only one used in practice, the large occipital nerve on the lobe and part of the helix, and the auriculotemporal nerve on the rest of the auricular flag. In this study, we would like to explore the justification for the topographic precision, adopted by traditional therapies, for non-invasive vagal stimulation on the concha.
| Status | Terminated |
| Enrollment | 10 |
| Est. completion date | November 21, 2019 |
| Est. primary completion date | November 21, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 60 Years |
| Eligibility | Inclusion Criteria: - Healthy volunteers, male and female, aged 18 to 60 years - BMI (Body mass index) <=30 - Not participating in another clinical study with an investigational product Exclusion Criteria: - Drug treatment for cardiological, neurological or anticoagulant purposes - History of diabetes, known neuropathy, high blood pressure, heart rhythm disorders, syncope or palpitation - Known cryoglobulinemia - Subject with Raynaud's syndrome - Intra-auricular device of the piercing type, - Psychoactive substance use, excessive alcohol consumption (>2 units per day chronically or >6 units per day recreationally) and tobacco (>5 cigarettes per day) - Subject unable to read French - Subject covered by Articles L1121-5 to 1121-8 of the Public Health Code, namely: - Pregnant, postpartum and breastfeeding women - Persons deprived of their liberty by a judicial or administrative decision - Persons undergoing psychiatric care under Articles L3112-1 and L3113-1 who are not covered by the provisions of Article L1121-8 - Minors - Persons of full age who are subject to a legal protection measure or who are unable to express their consent |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital Européen Marseille | Marseille | Paca |
| Lead Sponsor | Collaborator |
|---|---|
| Hôpital Européen Marseille | Aix Marseille Université |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Sinus variability | measured by cardiofrequency meter(ACTIWAVE ®) | 20 minutes | |
| Primary | Skin temperature changes | measured by thermocouples placed on the following fingers: thumb, middle finger and ear of the right hand. The values and times of the minimum and maximum temperatures (latency and amplitude of (CIVD) Cold-Induced VasoDilatation waves) are measured | 20 minutes | |
| Secondary | Pain reported by the participant | Measured by visual analogue scale; this scale ranges from 0 to 10; 0 being no pain, 10 being excruciating pain. | 20 minutes |